Carcinoma córtico-adrenal. Revisión de la literatura

Paton BL, Novitsky YW, Zerey M, et al. Outcomes of adrenal cortical carcinoma in the United States. Surgery. 2006;140:914-20.

https://doi.org/10.1016/j.surg.2006.07.035

Maluf DF, de Oliveira BH, Lalli E. Therapy of adrenocortical cancer: present and future. Am J Cancer Res. 2011;1:222-32.

Instituto Nacional de Cancerología (INC). Registro institucional de cáncer. Anuario estadístico 2009. Bogotá: INC; 2010.

Registro Poblacional de Cáncer de Cali, Universidad del Valle. Estadísticas, incidencia, 2007 [internet]. [citado: 18 de abril de 2012]. Disponible en: http://rpcc.univalle.edu.co/es/incidencias/Estadisticas/index.php

Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. . Eur J Endocrinol. 2 0 11;164:851-70 .

https://doi.org/10.1530/EJE-10-1147

Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005;12:667-80.

https://doi.org/10.1677/erc.1.01029

Young WF Jr. Management approaches to adrenal incidentalomas. Endocrinol Metab Clin North Am. 2000;29:159-85.

https://doi.org/10.1016/S0889-8529(05)70122-5

Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130-6.

https://doi.org/10.1002/cncr.23886

Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol. 2002;20:941-50.

https://doi.org/10.1200/JCO.2002.20.4.941

Libe R, Bertherat J. Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. Eur J Endocrinol. 2005;153:477-87.

https://doi.org/10.1530/eje.1.02004

Libe R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Related Cancer. 2007;14:13-28.

https://doi.org/10.1677/erc.1.01130

Soon PS, McDonald KL, Robinson BG, et al. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist. 2008;13:548-61.

https://doi.org/10.1634/theoncologist.2007-0243

Bertherat J, Bertagna X. Pathogenesis of adrenocortical cancer. Best Pract Res Clin Endocrinol Metab. 2009;23:261-71.

https://doi.org/10.1016/j.beem.2008.10.006

Barlaskar FM, Hammer GD. The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord. 2007;8:343-8.

https://doi.org/10.1007/s11154-007-9057-x

Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91:2027-37.

https://doi.org/10.1210/jc.2005-2639

Wandoloski M, Bussey KJ, Demeure MJ. Adrenocortical cancer. Surg Clin N Am. 2009;89:1255-67.

https://doi.org/10.1016/j.suc.2009.06.019

Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. . Best Pract Res Clin Endocrinol Metab. 2009;23:273-89.

https://doi.org/10.1016/j.beem.2008.10.008

Kumar R, Alavi A, Fanti S. Adrenocortical positron emission tomography/PET-CT Imaging. PET Clin. 2008;2:331-9.

https://doi.org/10.1016/j.cpet.2008.04.002

Medeiros LJ, Weiss LM. New development in the pathologic diagnosis of adrenal cortical neoplasms-a review. Am J Clin Pathol. 1992;97:73-83.

https://doi.org/10.1093/ajcp/97.1.73

Hofland de J, de Jong FH. Inhibins and activins; their roles in the adrenal gland and the development of adrenocortical tumors. Mol Cell Endocrinol. 2011 Jun 22. (Epub ahead of print).

Pabón N, Gómez C, Garavito G, et al. Carcinoma corticosuprarrenal: estado actual de nuestro conocimiento. Rev Colomb Cancerol. 2005;9:123-9.

Kuruba R, Gallagher SF. Current management of adrenal tumors. Curr Opin Oncol. 2008;20:34-46.

https://doi.org/10.1097/CCO.0b013e3282f301fd

Patalano A, Brancato V, Mantero F. Adrenocortical cancer treatment. Horm Res. 2009;71(Suppl 1):99-104.

https://doi.org/10.1159/000178049

Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27:4619-29.

https://doi.org/10.1200/JCO.2008.17.2775

Schteingart DE. Adjuvant mitotane therapy of adrenal cancer use and controversy. N Engl J Med. 2007;356:2415-8.

https://doi.org/10.1056/NEJMe078087

Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer. 2008;15:1043-53.

https://doi.org/10.1677/ERC-08-0103

Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol. 2004;5:718-26.

https://doi.org/10.1016/S1470-2045(04)01647-X

Suzuki H. Laparoscopic adrenalectomy for adrenal carcinoma and metastases. Curr Opin Urol. 2006;16:47-53.

https://doi.org/10.1097/01.mou.0000193378.14694.9b

Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma. Surgery. 1997;122:1212-8.

https://doi.org/10.1016/S0039-6060(97)90229-4

Berruti A, Fassnacht M, Baudin E, et al. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. J Clin Oncol. 2010;28:e401-2.

https://doi.org/10.1200/JCO.2009.27.5958

Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372-80.

https://doi.org/10.1056/NEJMoa063360

Fareau GG, López A, Stava C, et al. Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies. Anti-cancer Drugs. 2008;19:637-44.

https://doi.org/10.1097/CAD.0b013e328300542a

Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Related Cancer. 2005;12:657-66.

https://doi.org/10.1677/erc.1.01025

Khan TS, Imam H, Juhlin C, et al. Streptozotocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 20 0 0 ;11:1281-7.

Fassnacht M, Terzolo M, Allolio B, et al. Etoposide, doxorubicin, cisplatin, and mitotane versus streptozotocin and mitotane in adrenocortical carcinoma: preliminary results from the first international phase III trial: the FIRM-ACT study. Endocrine Abstracts. 2011;26:OC2.1.

Wortmann S, Quinkler M, Ritter C, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162:349-56.

https://doi.org/10.1530/EJE-09-0804

Quinkler M, Hahner S, Wortmann S, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine . J Clin Endocrinol Metab. 2008;93:2057-62.

https://doi.org/10.1210/jc.2007-2564

Samnotra V, Vassilopoulou-Sellin R, Fojo A, et al. A phase II trial of gefitinib monotherapy in patients with unresectable adrenocortical carcinoma (ACC). J Clin Oncol. 2007;25:15527.

Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third line therapy in patients with adrenocartical carcinoma. Eur J Endocrinol. 2012;166:451-8.

https://doi.org/10.1530/EJE-11-0918

Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/ third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Related Cancer. 2010;17:445-53.

https://doi.org/10.1677/ERC-09-0281

Lee JO, Lee KW, Kim CJ, et al. Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol. 2009;39:183-5.

https://doi.org/10.1093/jjco/hyn146

Chacon R, Tossen G, Loria FS, et al. Response in a patient with metastatic adrenal cortical carcinoma with thalidomide. J Clin Oncol. 2005;23:1579-80.

https://doi.org/10.1200/JCO.2005.03.195

Salboch A, Feng M, Griffith K, et al. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2011;80:1477-84.

https://doi.org/10.1016/j.ijrobp.2010.04.030

Polat B, Fassnacht M, Pfreunder L, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009;115:2816-23.

https://doi.org/10.1002/cncr.24331